medigraphic.com

2021, Number 3

<< Back Next >>

Enfermería Universitaria 2021; 18 (3)

Insulin based therapy in patients with type 2 diabetes mellitus. A narrative review

González-Wong C, Fuentes-Barría H, Aguilera-Eguía R

Language: Spanish
References: 56
Page: 368-381
PDF size: 360.68 Kb.


ABSTRACT

Introduction: Type 2 diabetes mellitus is one of the non transmissible chronic illnesses which have increased in prevalence during the last decades worldwide. Among the related treatments is the insulin based therapy. Nevertheless, the multiple and diverse controlled and commercial options of this therapy have generated confusion among both the users and health staff.
Objective: To describe some insulin-based therapy approaches to type 2 diabetes mellitus.
Development: The related technological advances have produced new diverse analog forms of insulin-based therapies. Among these, inhaling and blended forms can be highlighteddue to their efficacy in glucose control. Among the blended mixture, administration forms are the intensive action and the mobile action ones, which can use a human insulin analog as the key therapy element. The public systems, including the Chilean, have an important security role in the supervision and monitoring of the proper and correct dose administrations.
Conclusion: The diverse forms of insulin-based therapies for patients with type 2 diabetes mellitus include those with prolonged action insulin analogs but their use should be based on integral knowledge in order to avoid adverse effects. The findings of this review should be considered with caution due to the methodological limitations derived from the study design.


REFERENCES

  1. Gutiérrez-Rodelo C, Roura-Guiberna A, Olivares-Reyes JA. Mecanismos moleculares de la resistenciaa la insulina: una actualización. Gac Med Mex. 2017; 153(2): 214-28. https://bit.ly/34Au5l5

  2. Carillo-Larco RM, Bernabé-Ortiz A. Diabetes mellitus tipo 2 en Perú: una revisión sistemática sobrela prevalencia e incidencia en población general. Rev Peru Med Exp Salud Publica. 2019; 36(1):26-36. https://dx.doi.org/10.17843/rpmesp.2019.361.4027

  3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regionaldiabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the InternationalDiabetes Federation Diabetes Atlas, 9th ed. Diabetes Res Clin Pract. 2019; 157: 107843.https://doi.org/10.1016/j.diabres.2019.107843

  4. Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulinanalogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetesmellitus. Cochrane Database Syst Rev. 2018; (12): CD013228.https://dx.doi.org/10.1002/14651858.CD013228

  5. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and nationalage-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: Asystematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1736-88.https://dx.doi.org/10.1016/S0140-6736(18)32203-7

  6. Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism.Nat Rev Mol Cell Biol. 2018; 19(10): 654-72. https://dx.doi.org/10.1038/s41580-018-0044-8

  7. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medicalcare in diabetes-2021. Diabetes Care. 2021; 44(Suppl. 1): 15-33. https://doi.org/10.2337/dc21-S002

  8. International Diabetes Federation. Managing older people with type 2 diabetes. Global Guideline.Brussels, Belgium: IDF; 2013. https://bit.ly/3OTKqUi

  9. Sánchez-Arellano AA, Navarro-Contreras G, Padrós-Blázquez F, Cruz-Torres CE. Relación entre autoeficacia,apoyo social, adherencia al tratamiento y HbA1C por nivel de percepción de amenazaen pacientes con DM2. Nova scientia. 2020; 12(25): 1-22. https://doi.org/10.21640/ns.v12i25.2466

  10. Rivas-Alpizar EM, Soriano-Guerrero DB, Hernández-Gutiérrez C. Guía práctica para el personalmédico y de enfermería sobre la administración de insulina. MediSur. 2005; 3(2): 1-5.https://bit.ly/35VuWgr

  11. Kumar A, Kumar-Bharti S, Kumar A. Therapeutic molecules against type 2 diabetes: What wehave and what are we expecting? Pharmacol Rep. 2017; 69(5): 959-70.https://doi.org/10.1016/j.pharep.2017.04.003

  12. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017; 389(10085): 2239-51.https://dx.doi.org/10.1016/S0140-6736(17)30058-2

  13. Ighbariya A, Weiss R. Insulin resistance, prediabetes, metabolic syndrome: What should everypediatrician know? J Clin Res Pediatr Endocrinol. 2017; 9(Suppl. 2): 49-57.https://dx.doi.org/10.4274/jcrpe.2017.S005

  14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Managementof hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a positionstatement of the American Diabetes Association and the European Association for the Study ofDiabetes. Diabetes Care. 2015; 38(1): 140-9. https://dx.doi.org/10.2337/dc14-2441

  15. Cajigal-Pelegrin Y, Arguelles-Martínez O, Roque-Morgado M, Artiles-Pardo E. Características clínicas,epidemiológicas y metabólicas en diabéticos tipo 2 recién diagnosticados con insulina comoterapéutica transitoria. Medi ciego. 2018; 24(3): 4-13. https://bit.ly/3MRyPmK

  16. Gururaj-Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens:A review of their role in improving glycaemic control in patients with diabetes. PostgradMed J. 2016; 92(1085): 152-64. https://dx.doi.org/10.1136/postgradmedj-2015-133716

  17. Pérez A, Mendoza L. Insulinoterapia. Medicine. 2015; 11(92): 5510-8.https://dx.doi.org/10.1016/j.med.2015.12.004

  18. Freeland B, Farber MS. A Review of insulin for the treatment of diabetes mellitus. Home HealthcNow. 2016; 34(8): 416-23. https://dx.doi.org/10.1097/NHH.0000000000000446

  19. Woo VC. New insulins and new aspects in insulin delivery. Can J Diabetes. 2015; 39(4): 335-43.https://dx.doi.org/10.1016/j.jcjd.2015.04.006

  20. Bejarano-Roncancio JJ, Almarza-Labarca JC, Veloza-Naranjos AL. Análogos de insulina: relevanciaclínica y perspectivas futuras. Rev. Fac. Med. 2012; 60(4): 333-41. https://bit.ly/3FehDFs

  21. Espinoza-Hernández R, Ocharán-Hernández ME. Farmacocinética de la insulina inhalable: ADME(absorción, distribución, metabolismo y excreción). Rev Hosp Jua Mex. 2013; 80(1): 54-8.https://bit.ly/3vLBpFu

  22. Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-) long-acting insulinanalogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.Cochrane Database Syst Rev. 2020; 11(11): 1-252.https://dx.doi.org/10.1002/14651858.CD005613.pub4

  23. Vidal M, Colungo C, Jansà M. Actualización sobre técnicas y sistemas de administración de lainsulina (I). Av. diabetol. 2008; 24(3): 255-69. https://bit.ly/38NWXYS

  24. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, et al. New insulin delivery recommendations.Mayo Clin Proc. 2016; 91(9): 1231-55. https://doi.org/10.1016/j.mayocp.2016.06.010

  25. Jansà M, Colungo C, Vidal M. Actualización sobre técnicas y sistemas de administración de lainsulina (y II). Av. diabetol. 2008; 24(4): 347-54. https://bit.ly/38U8fut

  26. Chaves W, Martínez L, Díaz D, Hernández D, Sanabria M. Hipoglucemia en pacientes con diabetesmellitus en los servicios de urgencias de dos hospitales de Bogotá, 2015-2017. Revista Colomb.Endocrinología Diabetes Metab. 2019; 6(4): 269-76. https://doi.org/10.53853/encr.6.4.545

  27. Estebanez-Roque K, Rodrigues-Gomes da Silva A, Bravo-de Almeida Santos MH, Prates-Melo EC.Fatores de risco associados à hipoglicemia e análise de eventos adversos em uma terapia intensiva.Texto Contexto Enferm. 2018; 27(3): 1-11. https://doi.org/10.1590/0104-070720180003350016

  28. Titchenell PM, Lazar MA, Birnbaum MJ. Unraveling the regulation of hepatic metabolism by insulin.Trends Endocrinol Metab. 2017; 28(7): 497-505. https://dx.doi.org/10.1016/j.tem.2017.03.003

  29. Brunton S. Pathophysiology of type 2 diabetes: The evolution of our understanding. J Fam Pract.2016; 65(Suppl. 4). https://bit.ly/3KGuMIE

  30. Chen L, Xing Q, Li J, Zhou J, Yuan Y, Wan Y, et al. Injection technique education in patients withdiabetes injecting insulin into areas of lipohypertrophy: A randomized controlled trial. DiabetesTher. 2021; 12(3): 813-26. https://doi.org/10.1007/s13300-021-01013-1

  31. Thewjitcharoen Y, Prasartkaew H, Tongsumrit P, Wongjom S, Boonchoo C, Butadej S, et al. Prevalence,risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients withdiabetes: An old problem in a new era of modern insulin. Diabetes Metab Syndr Obes. 2020; 13:4609-20. https://doi.org/10.2147/DMSO.S282926

  32. Yoshida Y, Sumikawa M, Sugimori H, Yano R. Factors that affect symptoms of injection site infectionamong Japanese patients who self-inject insulin for diabetes. Healthcare (Basel). 2021; 9(4):402. https://doi.org/10.3390/healthcare9040402

  33. Yoshida Y, Takashima R, Yano R. Is skin disinfection before subcutaneous injection necessary?The reasoning of Certified Nurses in Infection Control in Japan. PLoS One. 2021; 16(1): e0245202.https://doi.org/10.1371/journal.pone.0245202

  34. Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A. Improvement of insulin injection technique:Examination of current issues and recommendations. Diabetes Educ. 2016; 42(4): 379-94.https://doi.org/10.1177/0145721716648017

  35. Tandon N, Kalra S, Balhara YPS, Baruah MP, Chadha M, Chandalia HB, et al. Forum for injectiontechnique and therapy expert recommendations, India: The Indian recommendations for bestpractice in insulin injection technique, 2017. Indian J Endocrinol Metab. 2017; 21(4): 600-17.https://doi.org/10.4103/ijem.IJEM_97_17

  36. Robb A, Reid B, Laird EA. Insulin knowledge and practice: A survey of district nurses in NorthernIreland. Br J Community Nurs. 2017; 22(3): 138-45. https://doi.org/10.12968/bjcn.2017.22.3.138

  37. Aschner P. Insulin therapy in type 2 diabetes. Am J Ther. 2020; 27(1): 79-90.https://doi.org/10.1097/MJT.0000000000001088

  38. García-Soidán FJ. Esquemas de inicio de insulinización, ajuste de dosis e intensificación de insulina.Diabetes Práctica. 2014; 5(supl. 7): 18-22. https://bit.ly/3LP9OIW

  39. Song X, Shi D, Cui Q, Yu S, Yang J, Song P, et al. Intensive insulin therapy versus plasmapheresis inthe management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): Study protocolfor a randomized controlled trial. Trials. 2019; 20: 365.https://dx.doi.org/10.1186/s13063-019-3498-x

  40. Choi H, Kramer CK, Zinman B, Connelly PW, Retnakaran R. Effect of short-term intensive insulintherapy on the incretin response in early type 2 diabetes. Diabetes Metab. 2019; 45(2): 197-200.https://dx.doi.org/10.1016/j.diabet.2018.01.003

  41. Lee YY, Lin YM, Leu WJ, Wu MY, Tseng JH, Hsu MT, et al. Sliding-scale insulin used for blood glucosecontrol: A meta-analysis of randomized controlled trials. Metabolism. 2015; 64(9): 1183-92.https://doi.org/10.1016/j.metabol.2015.05.011

  42. Christensen MB, Gotfredsen A, Nørgaard K. Efficacy of basal-bolus insulin regimens in the inpatientmanagement of non-critically ill patients with type 2 diabetes: A systematic review andmeta-analysis. Diabetes Metab Res Rev. 2017; 33(5): e2885. https://doi.org/10.1002/dmrr.2885

  43. Gómez-Cuervo C, Sánchez-Morla A, Pérez-Jacoiste Asín MA, Bisbal-Pardo O, Pérez-Ordoño L,Vila-Santos J. Effective adverse event reduction with bolus-basal versus sliding scale insulintherapy in patients with diabetes during conventional hospitalization: Systematic review andmeta-analysis. Endocrinol Nutr. 2016; 63(4): 145-56. https://dx.doi.org/10.1016/j.endonu.2015.11.008

  44. Colunga-Lozano LE, Gonzalez-Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez AV,Roman Y, et al. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus.Cochrane Database Syst Rev. 2018; (11): CD011296 1-92.https://dx.doi.org/10.1002/14651858.CD011296.pub2

  45. Krzymien J, Ladyzynski P. Insulin in type 1 and type 2 diabetes-should the dose of insulin beforea meal be based on glycemia or meal content? Nutrients. 2019; 11(3): 607.https://doi.org/10.3390/nu11030607

  46. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standardsof Medical Care in Diabetes-2021. Diabetes Care. 2021; 44(Suppl. 1): 111-24.https://doi.org/10.2337/dc21-S009

  47. Chen W, Qian L, Watada H, Li PF, Iwamoto N, Imori M, et al. Impact of diet on the efficacy of insulinlispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes:Subgroup analysis of the comparison between low mixed insulin and mid mixed insulinas starter insulin for patients with type 2 diabetes mellitus (CLASSIFY Study) randomized trial. J.Diabetes Investig. 2017; 8(1): 75-83. https://doi.org/10.1111/jdi.12547

  48. Meece J. Basal insulin intensification in patients with type 2 diabetes: A review. Diabetes Ther.2018; 9: 877-90. https://doi.org/10.1007/s13300-018-0395-3

  49. Donnelly LA, Zhou K, Doney ASF, Jennison C, Franks PW, Pearson ER. Rates of glycaemic deteriorationin a real-world population with type 2 diabetes. Diabetologia. 2018; 61: 607-15.https://doi.org/10.1007/s00125-017-4519-5

  50. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensusstatement by the American Association of Clinical Endocrinologists and American College ofEndocrinology on the comprehensive type 2 diabetes management algorithm-2018 executivesummary. Endocr. Pract. 2020; 26(1): 107-39. https://doi.org/10.4158/CS-2019-0472

  51. Christensen MB, Serifovski N, Herz AMH, Schmidt S, Gaede P, Hommel E, et al. Efficacy of advancedcarbohydrate counting and automated insulin bolus calculators in type 2 diabetes: TheBolusCal2 study, an open-label, randomised controlled trial. In: 54th EASD Annual Meeting of theEuropean Association for the Study of Diabetes. Diabetologia. 2018; 61(Suppl. 1): 402.https://doi.org/10.1007/s00125-018-4693-0

  52. Ulloa-Sabogal IM, Mejia-Arciniegas CN, Plata-Uribe EF, Noriega-Ramírez A, Quintero-Gómez DL,Grimaldos-Mariño MA. Proceso de enfermería en la persona con diabetes mellitus desde la perspectivadel autocuidado. Rev. cuba. enferm. 2017; 33(2): 404-17. https://bit.ly/3LSf3ra

  53. Fernández-Silva CA, Calisto-Mansilla VA, Valdebenito-Vivar J, Merino-Jara C. Revisión integrativade autoeficacia en el uso de insulina en personas diagnosticadas con diabetes tipo 2. Rev.iberoam. Educ. investi. Enferm. 2019; 9(4): 30-9. https://bit.ly/3KRJsEK

  54. Gallardo-Zanetta AM, Franco-Vivanco PV, Urtubey X. Experiencia de pacientes con diabetes ehipertensión que participan en un programa de telemonitoreo. Rev CES Med. 2019; 33(1): 31-41.http://dx.doi.org/10.21615/cesmedicina.33.1.4

  55. Bächler R, Mujica V, Orellana C, Cáceres D, Carrasco N, Davidson C, et al. Eficacia de un programaeducativo estructurado en población diabética chilena. Rev. méd. Chile. 2017; 145(2): 181-7.https://dx.doi.org/10.4067/S0034-98872017000200005

  56. Lutfiyya MN, Tomai L, Frogner B, Cerra F, Zismer D, Parente S. Does primary care diabetes managementprovided to Medicare patients differ between primary care physicians and nursepractitioners? J Adv Nurs. 2017; 73(1): 240-52. https://doi.org/10.1111/jan.13108




2020     |     www.medigraphic.com